Infiltrating monocytes and macrophages play a crucial role in the progression of HIV-1 infection in the CNS. Previous studies showed that activation of the CB 2 can attenuate inflammatory responses and affect HIV-1 infectivity in T cells and microglia. Here, we report that CB 2 agonists can also act as immunomodulators on HIV-1-infected macrophages. First, our findings indicated the presence of elevated levels of CB 2 expression on monocytes/macrophages in perivascular cuffs of postmortem HIV-1 encephalitic cases. In vitro analysis by FACS of primary human monocytes revealed a step-wise increase in CB 2 surface expression in monocytes, MDMs, and HIV-1-infected MDMs. We next tested the notion that up-regulation of CB 2 may allow for the use of synthetic CB 2 agonist to limit HIV-1 infection. Two commercially available CB 2 agonists, JWH133 and GP1a, and a resorcinol-based CB 2 agonist, O-1966, were evaluated. Results from measurements of HIV-1 RT activity in the culture media of 7 day-infected cells showed a significant decrease in RT activity when the CB 2 agonist was present. Furthermore, CB 2 activation also partially inhibited the expression of HIV-1 pol. CB 2 agonists did not modulate surface expression of CXCR4 or CCR5 detected by FACS. We speculate that these findings indicate that prevention of viral entry is not a central mechanism for CB 2 -mediated suppression in viral replication. However, CB 2 may affect the HIV-1 replication machinery. Results from a singleround infection with the pseudotyped virus revealed a marked decrease in HIV-1 LTR activation by the CB 2 ligands. Together, these results indicate that CB 2 may offer a means to limit HIV-1 infection in macrophages.
Introduction
Despite immune recovery in individuals on combination antiretroviral therapy, the frequency of HAND remains high for reasons that are not well understood [1] . The current understanding is that HIV-1-associated neurodegeneration is driven by chronic inflammatory responses in the brain, secondary to a low level of HIV-1 replication in the CNS reservoir cells (macrophages, microglia) [2, 3] . Treatment approaches targeting inflammation and HIV-1 replication should be beneficial for amelioration of HAND.
Cannabis has been recognized for its psychoactive properties for centuries and more recently for medicinal activities. Cannabinoids, the primary psychoactive compounds of cannabis, act through two well-characterized receptors that generate distinct physiological effects when activated. The psychoactive effects of cannabinoids are associated with the CB 1 receptor, whereas the CB 2 receptor (further in the text referred as CB 2 ) mainly mediates anti-inflammatory and immunomodulatory actions [4] . Cannabinoids have emerged recently as potential treatments for HAND. For example, cannabinoid receptor ligands are able to attenuate tissue inflammation and significantly reduce morbidity and mortality of SIV-infected macaques [5] . Medicinal cannabis reduces neurologic complications (neuropathic pain) in HIV-infected patients [6] . It has been proposed that the effects of medicinal cannabis may be associated with activation of the nonpsychoactive CB 2 receptor. In fact, up-regulation of CB 2 expression has been shown on perivascular macrophages/microglia, astrocytes, and brain endothelial cells in HIVE [7, 8] . Furthermore, CB 2 ligands suppress HIV-1 replication in microglia, decrease microglial migration toward HIV-1 Tat, protect neurons and endothelial cells against gp120 toxicity, and diminish neuroinflammation in a rodent model of HIVE [9 -13] . However, thus far, the role of CB 2 -selective activation in HIV-1 infection of macrophages has not been examined comprehensively.
In this study, we explore the use of highly specific CB 2 receptor agonists to attenuate HIV-1 infection in human macrophages. Our results indicate that there is a significant up-regulation of CB 2 expression upon monocyte differentiation to macrophages that is enhanced further by HIV-1 infection. Synthetic CB 2 receptor agonists markedly decreased HIV-1 replication (measured by RT activity). CB 2 activation may not appear to interfere with viral entry, as there was a lack of regulation by CB 2 receptor agonists on gene or surface protein expression of CXCR4 or CCR5. HIV-1 LTR activation and HIV-1 pol expression were suppressed by the agonists in infected macrophages. These data suggest that a possible hindrance to the HIV-1 replication machinery may be the mechanism of action behind the inhibition of HIV-1 by the CB 2 receptor.
MATERIALS AND METHODS

Reagents, cell culture, and HIV-1 infection
The following CB 2 -dimethoxyphenyl]-3-methyl-cyclohexanol)} was acquired from Organix (Woburn, MA, USA) and synthesized as described previously [14] . Unless otherwise specified, all other reagents were obtained from Sigma-Aldrich (St. Louis, MO, USA).
Primary human monocytes derived from six donors were acquired from the Human Immunology Core at the University of Pennsylvania (Philadelphia, PA, USA). The facility isolates monocytes using counterflow centrifugal elutriation, as described previously [15] . The monocytes were placed in 24-well plates within 24 h of isolation. Monocytes were maintained in DMEM, supplemented with 10% heat-inactivated, pooled human serum, 1% glutamine, 50 g/ml gentamicin, 10 g/ml ciprofloxacin, and 1000 U/ml highly purified human rM-CSF, which was present in the medium for the first 5 days of culture to promote differentiation and was then removed. Culture medium was changed every 3 days. After 7 days in suspension culture, MDMs were infected with HIV-1 ADA (a macrophage tropic strain; obtained from the AIDS Research and Reference Reagent Program, National Institutes of Health, Germantown, MD, USA) at a m.o.i. of 0.1 infectious virus particle/target cell. In pretreatment experiments, MDMs were exposed to the experimental treatment for 24 h before introduction of the virus. For post-treatments, the MDMs were infected with virus for 4 h, washed with DMEM, and then treated with the CB 2 ligand. Treatments were maintained for 7 days, with one-half medium replacement on Days 3, 5, and 7 after HIV was added to the cells. On Days 3, 5 and 7, culture medium was collected and stored at Ϫ80°C until it was assayed for HIV-1 RT activity. The reporter cell line TZM-bl was obtained through the NIH AIDS Research and Reference Reagent Program, Division of AIDS, National Institute of Allergy and Infectious Diseases; TZM-bl cells were generated by Dr. John C. Kappes, Dr. Xiaoyun Wu, and Tranzyme (Durham, NC, USA). The cells were grown in six-well plates in DMEM, 10% FBS, 100 U penicillin, and 0.1 mg/ml streptomycin. All cell-culture reagents (media, antibiotics, etc.) were purchased from Invitrogen/Life Technologies (Carlsbad, CA, USA).
Immunohistochemistry
Immunohistochemistry was performed on serial sections from postmortem paraffin-embedded brain tissue [16] . The analyzed tissue originated from frontal cortical regions from four cases of HIVE and from four seronegative, age-matched controls. The cases were provided by the National NeuroAIDS Tissue Consortium (Washington, DC, USA). With the use of standard immunohistochemistry methods, serial sections (5 in thickness) were generated and then baked at 65°C for 20 min, followed by deparaffinization and rehydration. The tissue was then subjected to antigen retrieval by incubating the sections at 100°C in 10 mM sodium citrate buffer (pH 6.0) for 20 min. Endogenous peroxidase activity was quenched by treating with Peroxidazed 1 (Biocare Medical, Concord, CA, USA) for 15 min. To block nonspecific antibody binding, the slides were incubated with 1% goat serum in 1ϫ PBS and 0.1% Triton X-100 (Sigma-Aldrich). For immunolabeling, the following primary antibodies were used: polyclonal antibodies against human CB 2 (Thermo Scientific, Rockford, IL, USA; diluted at 1:100 with overnight incubation), polyclonal antibodies to Iba-1 (Wako Chemicals USA, Richmond, VA, USA; diluted at 1:200 with overnight incubation), and mAb to HIV-1 p24 (Clone Kal-1; Dako, Carpinteria, CA, USA; diluted at 1:10 with overnight incubation). Detection was performed with anti-mouse or anti-rabbit secondary antibodies (Biocare Medical) in combination with the Mach 3 HRP-polymer system and the 3,3=-diaminobenzidine substrate (Biocare Medical). Normal rabbit or mouse IgG at the same concentrations as the primary antibodies served as negative controls. Counterstaining of the nuclei was performed using hematoxylin (Biocare Medical). Representative images shown in the first figure originate from previously published cases [16] . The control image is from Case Number 8, HIVE (middle) is from Case Number 2, and HIVE (bottom) is from Case Number 3. Clinical history of the cases used did not indicate treatment with antiretroviral therapy.
Real-time qPCR
Total cellular RNA was isolated from macrophages (1ϫ10 6 cells) on Day 7 post-HIV infection using the RNaqueous 4PCR kit, according to the manufacturer's directions (Ambion, Austin, TX, USA). RNA purity and concentration were determined with a NanoDrop ND-1000 spectrophotometer (Thermo Fisher Scientific, Fair Lawn, NJ, USA). Total RNA (2 g) was subjected to RT using the high-capacity cDNA RT kit, according to the manufacturer's directions (Applied Biosystems/Life Technologies, Carlsbad, CA, USA). The cDNA (diluted 1:20) template was then mixed with the Maxima Probe/ROX qPCR Master Mix (Fermentas, Hanover, MD, USA) and the corresponding human TaqMan gene expression assay (Applied Biosystems/ Life Technologies): CNR2: Hs00361490_m1; CXCR4: Hs00607978_s1; and CCR5: Hs99999149_s1. Maxima Probe/ROX qPCR Master Mix (2ϫ; Fermentas) was used to measure HIV-1 ADA Pol gene expression with the following oligonucleotide primers: 5=-GAAATTTGTACAGAAATGGAAAAGGAA-3= (forward) and 5=-TGAGTTCTCTTATTAAGTTCTCTGAAATCTAC-3= (reverse) and FAM-5=-TTGGGCTGAAATCCATACAATACTCCAGT-3=-TAMRA (Taqman probe). All controls and samples were run in triplicate in the same culture plate. GAPDH mRNA was measured with the Taqman gene expression assay, Hs02758991_g, and was used as a control to normalize the mRNA content in the samples tested. qPCR was performed on a StepOnePlus real-time PCR system (Applied Biosystems/Life Technologies). Raw data were analyzed with DataAssist software (Applied Biosystems/Life Technologies) using the ⌬⌬Ct method (relative quantification). Results are expressed in relative gene expression levels (fold) compared with the untreated control or the HIV-1-only condition.
Flow cytometry
Analysis of surface expression of CB 2 and HIV-1 coreceptors CXCR4 and CCR5 was determined by flow cytometry. Briefly, 1 ϫ 10 6 cells were placed in staining solution (2% BSA in PBS with 0.5% NaN 3 ) containing fluorophore-conjugated antibodies to CXCR4 (anti-CD184-allophycocyanin; BD Biosciences, Franklin Lakes, NJ, USA) and CCR5 (anti-CD195-PE; BD Biosciences) for 30 min on ice. For detection of CB 2 expression, the cells were incubated for 1 h with polyclonal antibodies to human CB 2 (Thermo Scientific), followed by detection with donkey anti-rabbit Alexa-488-conjugated antibodies. Cells were then washed and fixed in 2% methanol-free formaldehyde (Thermo Scientific) in 1ϫ PBS. Acquisition and analysis of the labeled cells were then performed using a FACSCanto II flow cytometer (BD Biosciences). Acquisition parameters and gating were controlled by FACSDiva software (BD Biosciences). Data analysis was performed with FlowJo software (Tree Star, San Carlos, CA, USA). The data represent the fluorescence intensity of gated populations (as determined by isotype-matched controls) of at least 100,000 events recorded in a single experiment that was repeated at least three times.
RT assay
The HIV-1 RT assay is a radiometric assay designed for the quantitative measurement of RT activity in cell culture, as described previously [17] . This assay is used to determine the propagation of HIV-1 in infected MDM cells. Please note that the RT assay (as used in this study) was not in the format used in screening for RT inhibitors, which involves challenging purified HIV-1 RT directly with the test compound. Rather, the results are representative of HIV-1 RT activity present in the medium of HIV-1-infected MDMs, untreated or treated with the indicated experimental compound at the given time-point. Briefly, 10 l culture supernatant was mixed with 50 l reaction mixture containing 5 g/ml poly(A) (GE Healthcare, Mickleton, NJ, USA) and oligo dT (1.57 g/ml; USB, Cleveland, OH, USA) in 50 mM Tris, pH 7.8, 7.5 mM KCl, 2 mM DTT, 5 mM MgCl 2 , 0.05% Nonidet P-40, and 0.5 Ci [␣- 
Single-round HIV-1 infection and ␤-gal assay
Recombinant luciferase-encoding HIV-1 virions were pseudotyped with the envelope from HIV-1 ADA , as described previously [18] . The pseudotyped virus was used for single-round infectivity assays in TZM-bl cells. Detection of ␤-gal was performed using the ␤-gal staining assay (Invitrogen/Life Technologies). After staining, images from each experimental condition were acquired using an Axio Observer Z1 microscope configured with an AxioCam HR camera (Carl Zeiss MicroImaging, Thornwood, NY, USA). Analysis was performed using AxioVision (v4.7) imaging software (Carl Zeiss MicroImaging). The number of stained cells was counted and averaged (three replicates) for each condition from at least three independent experiments.
Cell viability assay
After monocyte differentiation to macrophages (see above), the cells were infected with HIV-1 ADA at a m.o.i. of 0.1. Two hours after the initial infection, the indicated CB 2 agonist, AZT or vehicle control was added. Seven days postinfection, cell viability was assessed using calcein-AM (Invitrogen/ Life Technologies), according to the manufacturer's recommendations. The assay is based on the principle that intracellular esterase activity (in live cells) converts the nonfluorescent and cell-permeable calcein-AM into polyanionic calcein, which is retained and intensely fluorescent (excitation at ϳ495 nm and emission at ϳ515 nm). Calcein-AM was added at 1 M, and the cells were incubated for 30 min, followed by three rinses with 1ϫ PBS. Fluorescence emitted from live cells was measured at 495 nm (excitation)/530 nm (emission) on an M5 fluorescence plate reader (Molecular Devices, Sunnyvale, CA, USA). All measurements were performed in triplicate, and the data are represented as the percent viability from the uninfected control.
Statistical analysis
Results are presented as mean Ϯ sd or sem, and P values Ͻ 0.05 are considered significant. Data were analyzed using the Prism v5 software (GraphPad Software, La Jolla, CA, USA), and statistical significance was determined by performing unpaired two-tailed Student's t-test or ANOVA with the Dunnett's post-test. All in vitro studies were performed with cells from at least three different donors with multiple replicates (at least three).
RESULTS
Up-regulation of CB 2 expression in infiltrating monocytes/macrophages in cases of HIVE
It is well established that immune cells express CB 2 ; however, how this expression may change during HIV-1 infection remains unknown. Therefore, we first examined CB 2 expression in HIV-1-infected monocytes/macrophages in perivascular cuffs present in HIVE. Autopsy tissues derived from six patients with HIVE, four HIV-positive controls, and five control seronegative patients were immunostained for CB 2 . Clinical, pathologic, and demographic details of these cases have been published before [16, 19] . Figure 1 shows representative images of immunostains in two HIVE cases and one HIV-1-seronegative control. HIVE cases demonstrated strong staining for CB 2 in perivascular monocytes/macrophages and some microglia cells (Fig. 1B and C) . Macrophages and microglial cells were detected by immunoreactivity with antibodies to Iba-1 ( Fig. 1E and F) . Interestingly, a number of the Iba-1-positive cells showed CB 2 immunoreactivity. Immunolabeling for the HIV-1 core antigen, p24, showed variable staining in many of the CB 2 -positive cells ( Fig. 1H and I ). In addition to the monocytes/macrophages and microglia, microvascular endothelial cells featured enhanced CB 2 staining in the HIVE cases (Fig. 1 , compare A with B and C). In control cases, only marginal staining was observed for the endothelium and resident perivascular macrophages and rarely in microglial cells (Fig.  1A and D) . None of the cells in control cases demonstrated HIV-1 p24 positivity. Also, HIV-1-positive cases (without signs of encephalitis) featured an increased number of activated microglia and macrophages with variable intensity for CB 2 reactivity (data not shown). These results suggest that the increased expression of CB 2 in macrophages and microglia is associated with HIV-1 infection and neuroinflammation.
Expression of CB 2 in HIV-1-infected MDMs
To evaluate whether CB 2 expression changes as a function of differentiation (monocyte to macrophage) and HIV-1 infection, we examined the gene and protein expression profile of CB 2 in primary human monocytes. Isolated human peripheral blood monocytes from six healthy donors were used within 24 h or allowed to differentiate for 7 days by adhesion and exposure to M-CSF. Differentiated MDMs were uninfected or infected with the macrophage-tropic HIV-1 ADA for 7 days. qPCR and analysis by the ⌬⌬Ct method revealed a step-wise increase in CB 2 expression with the following pattern: monocytes Ͻ MDMs Ͻ HIV-1-infected MDMs ( Fig. 2A) . Relative (fold regulation) expression showed MDMs with a 5.47 Ϯ 1.07 increase over that observed for undifferentiated monocytes (set at 1). Infection of MDM with HIV-1 ADA significantly increased the CB 2 receptor gene expression even further, resulting in 7.41 Ϯ 0.94-fold up-regulation compared with monocytes and a 1.35-fold increase over uninfected MDMs. With the use of a similar experimental approach, we evaluated surface expression of CB 2 by FACS analysis. With the use of antibodies for CB 2 , which recognize epitopes in the extracellular N-terminus segment of CB 2 , FACS analysis showed a similar detection pattern as observed in the gene-regulation profile. Figure 2B shows representative histograms for detection of CB 2 along with MFI values. A fold induction of 1.76 in MDMs compared with monocytes was observed and a 2.28-fold increase in infected MDMs, in contrast to uninfected MDM. Together, these results are complimentary in that the increase in gene regulation translates into an increase in CB 2 protein expression. Furthermore, the analysis in primary cells appears consistent with the observations in Fig. 1 , suggesting that HIV-1 infection induces further elevation in CB 2 expression.
CB 2 receptor agonists inhibit HIV-1
Given the anti-inflammatory role that CB 2 plays in immune cells and the observations that the CB 2 receptor is not only present in HIV-1-infected MDMs but also appears up-regulated when compared with uninfected cells (Figs. 1 and 2) , we examined whether CB 2 ligands may affect HIV-1 infection. Differentiated MDMs were infected with HIV-1 ADA for 4 h (viral incubation period). The media were changed, and the infection was allowed to continue for 7 days (see Materials and Methods). Where indicated (Fig. 3) , infected MDMs were exposed to the potent CB 2 receptor agonist JWH133; K i ϭ 3.4 nM with ϳ200-fold selectivity for the CB 2 receptor over CB 1 [20] . Performed in parallel and with the same donor, the activity of HIV-1 RT activity was measured from the culture medium of infected cells at the end of 7 days. JWH133 in the "pretreated" groups were introduced 24 h prior to infection, whereas in the "post-treated" groups, JWH133 was added following the viral incubation period (Fig. 3A , pre-and posttreated). The addition of the CB 2 agonist resulted in a dosedependent decrease of RT activity. JWH133 at 1 M reduced the detectable RT activity in the medium by 34.6% and 68.9% when the agonist was introduced, pre-and post-treated, respectively. JWH133 at 10 M resulted in an 82.8% decrease in RT activity in the pretreated group and similarly, when the cells were post-treated. Administration of the CB 2 -inverse agonist/ antagonist SR144528 had no significant effect on RT activity; however, when coadministered with JWH133, it counteracted agonist effects completely (Fig. 3A) . Of note, the RT inhibitor, AZT (10 M), served as control for suppression of HIV-1 replication, thus resulting in decreased levels of RT activity in the medium of treated cells. The results also suggest that the effect of the CB 2 agonist on viral replication (RT assay) may not be a result of interference with viral entry. This is surmised from the post-treated group, where the agonist was added following the 4-h virus incubation period. The results also show that the inhibition observed in the presence of the CB 2 agonist requires a continued and prolonged exposure, as the effect is limited at earlier time-points (Fig. 3B) . Although a downward trend was observed when JWH133 was present, RT activity at Day 3 was not reduced significantly. A similar trend was observed at Day 5, with the only significant difference (36% inhibition) apparent at the higher concentration of JWH133. Two additional synthetic CB 2 agonists were also investigated, GP1a (K i ϭ0.037 nM) and O-1966 (K i ϭ23 nM) [14, 21] . As JWH133 appeared more effective when added as a post-treatment (after the introduction of HIV-1), the addition of GP1a or O-1966 was done in a similar fashion (Fig. 3C and  D, respectively) . The results indicated a marked decrease in the degree of RT activity when either of the two agonists was added to the cells. GP1a resulted in a 87.4% (2 M) and 88.7% (10 M) decrease in detectable RT activity. Likewise, the addition of the novel resorcinol-based compound O-1966 provided a 73.3% (1 M), 85% (5 M), and 87.6% (10 M) attenuation in RT activity present in the culture medium. Interestingly, like JWH133, GP1a and O-1966 had no significant effect on RT activity at Days 3 and 5 (data not shown). Cell viability does not appear to be a factor contributing to the decreased level of RT activity. As reported by others [22, 23] , the assessment of JWH133 on cell viability did not compromise cell survival (data not shown). GP1a and O-1966 did not change the viability of infected MDMs at the concentrations used above (Fig. 3E) . A decrease in viability (20%) was evident only when GP1a was used at a much higher concentration (Fig. 3E) . The results from these RT assays suggest that the up-regulation in CB 2 expression in infected cells offers the possibility to use CB 2 agonists to suppress HIV-1 replication.
CB 2 activation in MDMs does not affect the expression of CXCR4 or CCR5
In light of the inhibitory effect that CB 2 receptor agonists have on HIV-1 RT activity, it is possible that CB 2 signaling alters the expression of HIV-1 coreceptors, thereby preventing re-entry of HIV-1 virions into the cells. To test this possibility, expression profiles for CXCR4 and CCR5 were evaluated by FACS and gene expression (Fig. 4) . Figure 4A and B shows representative histograms for the expression of CXCR4 and CCR5 (respectively) by FACS in MDMs that were treated with JWH133 (10 M), GP1a (10 M), or O-1966 (10 M) for 24 h. As indicated, there was no change in the level of these HIV-1 coreceptors in the presence of the agonists. Interestingly, HIV-1 infection (7 days) did not change gene expression for CXCR4 (Fig. 4C) or CCR5 (Fig. 4D) in MDMs. Therefore, CB 2 -mediated inhibition of HIV-1 in primary human macrophages does not involve down-regulation of CXCR4 or CCR5.
CB 2 agonists inhibit the activity of the HIV-1 LTR
To evaluate whether CB 2 signaling may affect the activity of the HIV-1 LTR, single-round infection of the TZM-bl reporter cell line was used. Pseudotyped envelope-deficient HIV-1 virions were produced by cotransfection in 293T cells of a NL4-3 HIV-1 backbone DNA construct, along with a separate DNA construct encoding for the HIV-1 ADA envelope. Purified, pseudotyped viruses were then introduced to TZM-bl cells, which stably express CXCR4 and CCR5 and also contain the HIV-1 LTR-driven ␤-gal reporter gene. The infection was allowed to occur for 6 h, at which point, the medium-containing virus was removed and changed to media containing JWH133 (1 M) or O-1966 (1 M). Figure 5A shows the results from the ␤-gal assay performed at 48 h after initiation of infection. Compared with untreated cells, JWH133 produced a 58% decrease in the number of ␤-gal-positive cells. O-1966 had a comparable effect with JWH133, resulting in 59% inhibition. To further validate the inhibition of the HIV-1 LTR, qPCR studies in primary MDMs were also performed for measurement of the level of HIV-1 pol transcription. MDMs infected with HIV-1 ADA , as described earlier, were exposed to the indicated CB 2 ligands (Fig. 5B) . Analysis of fold-change regulation of HIV-1 pol copy number revealed a significant decrease at the concentrations tested for the CB 2 agonists, whereas no change was observed 
DISCUSSION
The CB 2 and the CB 1 receptors comprise the cannabinoid receptor family. Unlike the CB 1 , the activation of the CB 2 recep- tor does not elicit psychoactive effects but rather promotes anti-inflammatory responses [24] . To date, the effect of CB 2 on HIV-1-infected macrophages has remained largely unknown. Such information is of great interest in the context of HIV-1 neuropathogenesis, as infection of monocytes/macrophages is thought to be the primary cause of how HIV-1 infiltrates the CNS [25, 26] . Thus far, several studies have demonstrated CB 2 expression in microglial cells, perivascular macrophages, and T cells in SIV encephalitis [27] . More recently, a study of HIVE from postmortem cases also showed a marked increase in CB 2 receptor expression in microglia, astrocytes, and perivascular cells [8] . Another example of the CB 2 receptor up-regulation in HIVE can be found in the relevant murine model of neuroAIDS [13] . The authors showed that the CB 2 receptor, but not the CB 1 or the orphan cannabinoid receptor GPR55, was up-regulated in HIVE brains in an animal model [13] . Our results are in agreement with these previous studies but also further add that in HIVE, microvessels and HIV-1-infected monocytes/macrophages in the perivascular space show up-regulated levels of the CB 2 . The up-regulation of the CB 2 on microglial cells and on infiltrating immune cells has prompted the notion that up-regulation of the receptor and binding to endocannabinoids may act as a triggering mechanism to attenuate inflammation. Moreover, regional increases in cannabinoid receptor expression have been shown to increase potency and efficacy of exogenous agonists at sites of end-organ injury [28] .
Up-regulation of CB 2 is a key observation that could allow for targeting of the CB 2 receptor to 1) minimize the inflammatory effects of HIV-1 harboring mononuclear cells and 2) reduce viral infection (the hypothesis presented in this study). Therefore, with the increasing availability of novel synthetic, highly specific CB 2 agonists, we investigated whether HIV-1 could be inhibited upon CB 2 activation on macrophages infected with the M-tropic HIV-1 ADA strain. We first examined the expression of CB 2 in primary human monocytes, MDMs, and MDMs infected with HIV-1. The results for protein and gene expression showed the following increased order of CB 2 receptor expression: monocytes Ͻ MDMs Ͻ HIV-1-infected MDMs. These results, obtained from multiple donors, suggest that CB 2 expression is altered as a function of monocyte differentiation and activation. Up-regulation of the receptor by activation appears to be a common phenomenon in inflammation [28, 29] . Earlier, we reported on the increase of CB 2 receptor levels in brain endothelial cells after exposure to IL-1␤, TNF-␣, and LPS [19] . Others have reported on increased CB 2 receptor expression on activated microglia as result of Acanthamoeba culbertsoni-mediated neuroinflammation [30] . In terms of HIV-1-induced activation, our study is the first (that we are aware of) to show that HIV-1 infection up-regulates the expression of CB 2 in macrophages. Interestingly, Raborn and Cabral [31] used U937 (a monocytic cell line) to show that the HIV-1 Tat has no effect on CB 2 expression. Therefore, HIV-1 accessory proteins, such as the transactivator Tat, may not cause induc- tion in CB 2 receptor levels, but rather, cellular responses to direct viral infection do. We next examined whether the enhanced presence of the CB 2 receptor could offer a therapeutic opportunity to curb HIV-1 infection. Indeed, the CB 2 agonist JWH133 demonstrated a dose-dependent inhibition (up to 82%) in HIV-1 RT activity in MDMs infected for 7 days. Importantly, the addition of JWH133 prior to or after HIV-1 infection provided comparable levels of inhibition. These results are complementary with those by Costantino et al. [32] , showing Ͼ40% inhibition in HIV-1 infection in primary CD4 ϩ T cells using a similar concentration (1 M) of JWH133. Similar observations were also found in HIV-1-infected microglial cells and CD4
ϩ T cells using WIN55,212-2 [33] . A dual agonist for CB 1 and CB 2 receptors, WIN55,212-2 was shown to limit HIV-1 p24 expression by ϳ 60% in microglia and CD4 ϩ T cells [33] . A follow-up study from the same group using the CB 2 receptor agonist JWH015 reported a 40% inhibition in HIV-1 p24 expression in infected microglial cells [9] , ascertaining that the HIV-1 suppression by WIN55,212-2 in microglial cells was, in part, a result of CB 2 -related effects. To ensure CB 2 receptor specificity, our analysis included the reverse agonist/antagonist SR144528. Indeed, SR144528, whether coadministered with the agonist before or after the onset of HIV-1 infection, completely eliminated the effects of the agonist. In addition to JWH133, two recently discovered and potent CB 2 agonists, GP1a and O-1966, were also tested for HIV-1 inhibition. GP1a and O-1966, added after HIV-1 introduction and replenished during a 7-day infection, revealed an inhibition of up to 88% and 85% in RT activity, respectively. Thus, the efficacy of reducing HIV-1 RT activity can be achieved to similar levels with CB 2 receptor agonists of varied chemical composition.
To understand the mechanism behind how the agonist affects HIV-1 infection in macrophages, we turned to evaluation of the HIV-1 coreceptors. Previously, it has been suggested that one possible consequence of CB 2 signaling is that it may affect the expression of HIV-1 coreceptors, CXCR4 and CCR5 [9] . Our observations in macrophages support results by other groups showing no effect of CB 2 on CXCR4 expression in CD4 ϩ T cells [32] . Here, we provide evidence that the CB 2 agonist does not alter surface protein expression of CXCR4 or its gene regulation in MDMs. Similarly, the CB 2 agonist did not change surface protein or gene expression of CCR5 in MDMs. These results are in contrast to the inhibitory effect that WIN55,212-2 has on CCR5 expression in microglia and that reported for GP1a in CD4 ϩ T cells (human PBLs) [9, 13] . However, in the same study with GP1a, CCR5 expression in CD8 ϩ cells was unchanged. Perhaps, unlike CXCR4, CCR5 could be a regulatory target of CB 2 receptor signaling in certain cell types but not others. Our results therefore suggest that in MDMs, there may not be interference in HIV-1 viral entry, at least not at the level of coreceptor expression, as a result of CB 2 activation.
As the effect on the HIV-1 coreceptors did not seem to provide a plausible explanation for how the CB 2 agonist inhibits HIV-1 infection, we next evaluated the activity of the HIV-1 LTR. With the use of single-round infections on the reporter cell line TZM-bl, which features the HIV-1 LTR-driven ␤-gal gene, the effects of CB 2 agonists were evaluated. The results O-1966 . Moreover, results of HIV-1 pol copy number substantiate the observations of the LTR, as relative expression of pol was reduced significantly by all CB 2 agonists tested. In light of these results, it is plausible that CB 2 signaling could interfere with full activation of the HIV-1 LTR. Admittedly, how the HIV-1 LTR may be inhibited by the CB 2 receptor is not known at this time, but it is the subject of ongoing studies in our laboratory. It is reasonable to speculate that a possible explanation may come from cellular transcription factors that share participation in proinflammatory responses and activation of the HIV-1 LTR. In fact, studies using ⌬ 9 THC, a partial agonist of CB 1 and CB 2 , have shown inhibition of NF-B in the macrophage cell line Raw 264.7 [34] . Furthermore, with the use of reporter assays, Borner and colleagues [35] demonstrated inhibition of NFAT and NF-B by ⌬ 9 THC or JWH015 (a CB 2 receptor agonist) in naïve and stimulated Jurkat cells. Accordingly, it is conceivable that transcription factors involved in the transactivation of the HIV-1 LTR could be targeted for inhibition upon stimulation of the CB 2 .
The effects of CB 2 activation have been well characterized as a means to reduce inflammatory responses in various cells types, particularly those of the immune system [24] . To date, however, no study has exclusively focused on whether CB 2 receptor activation may affect HIV-1 expression in macrophages. The study presented in this report invites the possibility of using CB 2 receptor agonists as a means to limit HIV-1 replication in infected macrophages. We show that synthetic CB 2 agonists provide a similar effect on HIV-1 infection, whether applied before or after the onset of infection. The findings also seem to implicate attenuation of the HIV-1 replication machinery rather than a hindrance to viral entry upon addition of the agonists. It should be noted that aside from affecting HIV-1 infection in primary macrophages, as reported here, CB 2 receptor agonists have pleiotropic effects in macrophages that may further lessen the burden of HIV-1. These effects include a decrease in overall proinflammatory response and possible inhibition in monocyte/macrophage migration into the CNS [13, 31] . Although immunoregulatory, it is also important to point out that activation of the cannabinoid receptor system is not immunosuppressive. Systemic administration of GP1a (in a mouse model of HIVE) and the now U.S. Food and Drug Administration-approved use of ⌬ 9 THC for AIDS-related wasting has not been shown to have adverse consequences on immune function [36, 37] . Therefore, the role of the CB 2 receptor in HIV-1 infection merits further investigation and testing of novel, synthetic CB 2 agonists. AUTHORSHIP N.L.R., S.F., S.R., and S.F.M. carried out the experiments in this study. S.H.R. and Y.P. designed experiments, analyzed data, and wrote the manuscript. X.W. and W-z.H. contributed vital reagents and materials.
